Scientific Background

All cells contain specific pathways that are targeted at helping proteins fold correctly, and others that are targeted at breaking down misfolded, toxic proteins. Certain neurons in the brain appear to be especially vulnerable to toxicity induced by specific protein aggregates. In the case of Alzheimer's and Parkinson's disease, there is growing evidence of an imbalance between the production and removal of aggregated, toxic proteins. The buildup of such toxic proteins ultimately results in the behavioral and cognitive pathologies of these diseases.

Link Medicine leverages a deep biological understanding of neurodegenerative disease progression to develop novel methods to reduce protein aggregation before it occurs. The mechanistic aim is to reduce existing, toxic aggregates in neurons, slowing or halting disease progression.


Overview Disease Areas Scientific Background Our Approach	Scientific Background All cells contain specific pathways that are targeted at helping proteins fold correctly, and others that are targeted at breaking down misfolded, toxic proteins. Certain neurons in the brain appear to be especially vulnerable to toxicity induced by specific protein aggregates. In the case of Alzheimer's and Parkinson's disease, there is growing evidence of an imbalance between the production and removal of aggregated, toxic proteins. The buildup of such toxic proteins ultimately results in the behavioral and cognitive pathologies of these diseases. Link Medicine leverages a deep biological understanding of neurodegenerative disease progression to develop novel methods to reduce protein aggregation before it occurs. The mechanistic aim is to reduce existing, toxic aggregates in neurons, slowing or halting disease progression.